Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 24, 2012, under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,050,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,467.0 pence per share; lowest price paid was 1,459.0 pence per share.
- Treasury Holdings (Settled): 493,258,927 shares, representing 9.01% of total issued share capital.
- Treasury Holdings (Including Unsettled): 497,108,927 shares, representing 9.98% of current total voting rights.
- Shares in Issue (Excluding Treasury): 4,978,809,907 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,050,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 9.98% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (493,258,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (9.98% held in Treasury including unsettled shares).
- Check the remaining authorized share repurchase limit under the May 3, 2012 shareholder mandate.
- Review the settlement status of the 1,050,000 shares purchased on August 24, 2012.